Freslon J L, Giudicelli J F
Br J Pharmacol. 1983 Nov;80(3):533-43. doi: 10.1111/j.1476-5381.1983.tb10726.x.
When administered to young spontaneously hypertensive rats (SHRs), dihydralazine (25 mg kg-1, daily) and captopril (100 mg kg-1, daily) prevent with the same efficacy genetic hypertension development (GHD). Dihydralazine treatment increased vascular mesenteric compliance, as shown by a significant decrease in the stiffness of the vessels (-27%), and induced slight reductions in contractility (-12%) and in wall to lumen (W/L) ratio (-15%). After treatment withdrawal, all these parameters returned to control values within 7 weeks, as did blood pressure. Captopril treatment also strongly increased the mesenteric vessels compliance, vessel stiffness being decreased by 16%, and reduced their contractility (-15%) and their W/L ratio (-30%). These effects as well as those exerted on blood pressure persisted up to 7 weeks after treatment ceased although there was a slight trend to a progressive reduction in the intensity of both phenomena. These experiments show that captopril but not dihydralazine has a long-lasting effect in opposing the functional and morphological vascular alterations occurring during GHD in SHRs and this phenomenon probably contributes to a large extent to the sustained preventive effects of the drug against GHD.
给幼年自发性高血压大鼠（SHRs）每日分别灌胃肼屈嗪（25 mg/kg）和卡托普利（100 mg/kg），二者预防遗传性高血压发展（GHD）的效果相同。肼屈嗪治疗可增加肠系膜血管顺应性，表现为血管僵硬度显著降低（-27%），并使收缩性轻度降低（-12%）以及壁腔比（W/L）轻度降低（-15%）。停药后7周内，所有这些参数以及血压均恢复至对照值。卡托普利治疗也显著增加肠系膜血管顺应性，血管僵硬度降低16%，并降低其收缩性（-15%）和W/L比（-30%）。这些作用以及对血压的作用在停药后7周内持续存在，尽管这两种现象的强度有逐渐轻微降低的趋势。这些实验表明，卡托普利而非肼屈嗪对SHRs在GHD期间发生的血管功能和形态改变具有持久的对抗作用，这种现象可能在很大程度上促成了该药物对GHD的持续预防作用。
